## THE UNIVERSITY OF WARW1

## **Chemistry Tipping the Biological Seesaw**

Sophie C. Royall & David J. Fox\*

Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, U.K. *Email: s.c.royall@warwick.ac.uk, d.j.fox@warwick.ac.uk* 

During a biological inflammatory response, patrolling leukocytes (white blood cells) release chemokines - a type of peptide cytokine - to summon other leukocytes. Inhibition of this process could provide a mechanism for new anti-inflammatory drugs.

Traditionally inhibition has been sought by blocking chemokine receptors with antagonists, but we have found useful molecules by inhibiting functional cell migration – with great success.

We would not have discovered **Broad-Spectrum Chemokine Inhibitors** (BSCIs) using a receptor antagonist approach as our functional screening approach has discovered a new biological target for anti-inflammatory drug design – the sstr<sub>2</sub> receptor.

> Sometimes inflammation is inappropriate and can exacerbate certain **diseases** for example cancer, arthritis and asthma.

 $\succ$  Due to their role in initiating inflammation chemokines are therefore a good target for antiinflammatory drugs - for example **BSCIs**.

> NR58-3.14.3 is a BSCI. It is a cyclic peptide with the critical motif being WIO. chemokine inhibition


The aim of my project is to synthesise a catalogue of molecules analogous to both somatostatin and BSCIs to investigate the important part of the molecules for tipping sstr<sub>2</sub> from GH to BSCI function. somatostatin **BSCIs** 

sstr<sub>2</sub> receptor


sstr<sub>2</sub> receptor

Somatostatin is a peptide involved in growth hormone (GH)regulation.<sup>2</sup>


> It is a cyclic peptide with the critical motif being KWF.<sup>3</sup>



> An example of an sstr<sub>2</sub> ligand based on the WKF motif.





 $\succ$  FX97L is a 40 pM BSCI.<sup>1</sup> The Q motif is mimicked by a caprolactam which retains the amide and has to be a successful been found pharmacological component.



FX97L 40 pM BSCI

>However, it has been discovered that BSCIs do not bind to chemokine receptors but to the **sstr<sub>2</sub>** receptor for somatostatin.






sstr<sub>2</sub> ligand based on WKF critical motif


Functional selectivity is the ability for a receptor to have different functions depending on the molecule to which it is bound.

>The sstr<sub>2</sub> receptor therefore displays functional selectivity when somatostatin is bound GH is affected BSCIs but when bound are chemokines are affected.<sup>4</sup>

0¥<sup>0H</sup>



> Synthesis:



> Future Work – The balance of BSCI vs. GH regulating activity for these compounds will be tested in a range of in vitro and in vivo models testing leukocyte migration, anti-inflammatory activity, sstr<sub>2</sub> binding and GH regulation.

1. D. J. Fox, J. Reckless, H. Lingard, S. Warren and D. J. Grainger, J. Med. Chem., 2009, 52, 3591-3595. 2. B. A. Hay, B. M. Cole, F. DiCapua, G. W. Kirk, M. C. Murray, R. A. Nardone, D. J. Pelletier, A. P. Ricketts, A. S. Robertson and T. W. Siegel, *Bioorg. Med. Chem. Lett.*, 2001, 11, 2731-2734. 3. D. J. Fox, J. Reckless, S. M. Wilbert, I. Greig, S. Warren and D. J. Grainger, J. Med. Chem., 2005, 48, 867-874. 4. A. Schonbrunn, Mol. Cell. Endocrinol., 2008, 286, 35-39.

Thanks to Funxional Therapeutics Ltd , Dr D. J. Grainger & Dr D J Fox